Ouster Short Sellers Add Pressure Before Q3 Report

OUST has accumulated short interest worth 11.6% of its free float, a level that has crept higher over the past week even as the stock lost 12% of its value.

Short sellers added roughly 400,000 shares to their position over the past seven days, bringing estimated short interest to 6.94 million shares. That is up 6.1% on the week and 3.3% over the past month. The build is notable because it continued through a sharp price decline rather than pausing on the way down. The last time shorts were heavier was in mid-October, when the position briefly reached 7.6 million shares before covering pulled it back. That covering proved temporary: the position has since rebuilt to within range of those highs.

The borrow market tells a more relaxed story. Cost to borrow is modest at 0.54%, up only fractionally on the week, and availability remains well above 100%, meaning there are roughly 41 million shares available to lend against the 6.9 million already borrowed. That is a loose lending environment by any measure. Availability did tighten by around 10% over the week, from roughly 138% to 124%, which tracks the increase in short demand, but it remains far from the kind of squeeze territory that would pressure shorts to cover. Options positioning adds little urgency to the picture: the put/call ratio of 0.47 is barely above its 20-day average of 0.46, well within normal range and far below the 52-week high of 0.57. Options traders are not loading up on downside protection.

The Street moved on the stock today, the day after a previous ORTEX earnings preview flagged that analyst targets had not yet adjusted to the selloff. Three analyst actions landed on November 4. Cantor Fitzgerald upgraded to Overweight with a $45 target. Amerx cut its target from $54 to $52.50 while holding an Overweight rating. Rosenblatt reiterated its Buy and kept its target at $53. All three targets remain well above the $28.98 close, and the consensus mean of $59.40 reflects older targets from Northland Capital Markets ($60) and Oppenheimer ($57) set in July. Taken together, the Street is re-engaging after the selloff rather than walking away, though the gap between targets and price is too wide to reflect genuine near-term conviction on valuations. The price-to-book has compressed to 3.6x from above 5.5x a month ago, and EPS surprise ranks in the 93rd percentile, but the company earns negative margins and carries a short score of 62.3, placing it in the bottom 6% of the market on that measure.

The insider register shows September sales by several executives, the CEO included, all conducted under pre-arranged 10b5-1 plans, which limits their signal value. The only open-market activity of note was a small director grant in early October. Among the largest holders, Vanguard Capital Management filed a fresh Schedule 13G on October 30 disclosing a 5% stake of 3.6 million shares. BlackRock and State Street both added to positions through the September quarter. No activist 13D is on the register.

OUST's closest peer by correlation, AEVA, fell 14.4% on the week, almost exactly in line with OUST. APH bucked the direction with a 7.6% gain, and FN surged 15.5% in a single session. The concentrated weakness in lidar-adjacent names suggests sector pressure rather than a company-specific catalyst, though the November 5 earnings report now provides the next data point that will distinguish the two.